COMMUNIQUÉS West-GlobeNewswire

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
11/05/2026
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM - [...]
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
11/05/2026
CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential accelerated drug development WALTHAM, [...]
AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases
11/05/2026
Collaboration brings AGC Biologics’ advanced therapy expertise and global footprint to OTXL’s network, supporting a sustainable path from clinical development to commercial access for therapies serving the smallest [...]
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA
11/05/2026
CONVOCATION À L’ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE DE IBA SA – MERCREDI 10 JUIN 2026, À 11H00 – Cher Actionnaire, Nous avons l’honneur de vous convoquer à une Assemblée Générale Extraordinaire d’IBA (l’ « AGE » ) au [...]
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
11/05/2026
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis HOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics [...]
Disc Medicine to Participate in Upcoming Investor Conferences
11/05/2026
WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
11/05/2026
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions [...]
The Next Generation of the GLP-1 Revolution Is Already Underway
11/05/2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of [...]
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA
11/05/2026
CONVENING NOTICE TO THE ORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY, JUNE 10, 2026, AT 10:00 A.M. – Dear Shareholder, We have the honor of convening you to the Ordinary General Meeting (the " OGM ") of IBA to be [...]
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
11/05/2026
Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on [...]
Leo International Precision Health AG Plans Acquisitions of Nine Additional Assets in Asia and Europe to Accelerate the Commercialization of Its AI-Driven Portfolio Solutions
11/05/2026
Leo International Precision Health AG Plans Acquisitions of Nine Additional Assets in Asia and Europe to Accelerate the Commercialization of Its AI-Driven Portfolio Solutions Expected total transaction volume of EUR 400 [...]
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
11/05/2026
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced [...]
Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™
11/05/2026
New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment ROMEOVILLE, Ill., May 11, 2026 [...]
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
11/05/2026
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ” ), a clinical-stage biotech [...]
CPTx appoints Edward Rebar as Chief Scientific Officer
11/05/2026
Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform David Maier appointed to expanded role as CPTx Chief Business Officer [...]
Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026
11/05/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
11/05/2026
Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture [...]
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
11/05/2026
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]

Pages